Epstein-Barr Virus Linked to Lupus in Groundbreaking New Study
Table of Contents
A new study published November 14, 2025, reveals a potential causal link between the ubiquitous Epstein-Barr virus (EBV) and the development of systemic lupus erythematosus, an autoimmune disease affecting approximately 5 million people worldwide. Researchers at Stanford Medicine have identified a specific mechanism by which the virus, carried by an estimated 95% of the global population, may trigger the debilitating condition.
The findings, published in Science Translational Medicine, represent a significant leap forward in understanding lupus, a disease where the immune system mistakenly attacks the body’s own tissues, specifically the contents of cell nuclei. For years, an association between EBV and lupus has been suspected, but this research is the first to demonstrate the underlying biological process.
Unveiling the Mechanism: Altered B Cells Hold the Key
The research centers on a small subset of B cells, a type of white blood cell crucial to the immune response. According to one researcher, “This is the most shocking finding that has emerged from my laboratory in my entire career.” The team discovered that in individuals with lupus, a significantly higher proportion of B cells are infected with EBV compared to healthy individuals – a 25-fold increase, rising from fewer than 1 in 10,000 to approximately 1 in 400.
This disparity was previously difficult to detect due to the low number of infected cells. To overcome this challenge, the Stanford Medicine team developed a high-precision sequencing system, allowing them to pinpoint and analyze the infected B cells with unprecedented accuracy.
How EBV Activates Autoimmunity
The study reveals that even a small number of EBV-infected B cells can initiate a powerful autoimmune response. Latent EBV, while typically inactive, occasionally prompts infected B cells to produce a viral protein called EBNA2. This protein acts as a “molecular switch,” activating genes within the B cell that were previously dormant.
These activated genes produce proteins that further amplify the inflammatory response, stimulating other immune cells – specifically helper T cells – to attack the nucleus of cells. These helper T cells then recruit additional B cells, creating a self-perpetuating cycle of inflammation. “When that ‘militia’ is reinforced, it does not matter whether any of the newly recruited antinuclear B cells are infected by EBV or not,” the researchers summarize. “If there are enough of them, the result is a lupus flare.”
The EBV Puzzle: Why Not Everyone Develops Lupus?
While the vast majority of people carry EBV – often contracting it in childhood through everyday activities like sharing utensils or kissing, earning it the nickname “the kissing disease” – only a fraction develop lupus. As one researcher noted, “Pretty much the only way not to get EBV is to live in a bubble.” The study suggests that variations in EBV strains may play a role, with certain strains potentially being more likely to trigger the transformation of infected B cells into these “driver” cells of autoimmunity.
Further research is needed to explore this possibility and to determine whether targeting EBV could lead to new therapies for lupus. The findings offer a promising new avenue for understanding and potentially preventing this chronic and often debilitating autoimmune disease.
Source: DW
